Polyprodrug with glutathione depletion and cascade drug activation for multi-drug resistance reversal

被引:63
|
作者
Xiao, Xuan [1 ,2 ]
Wang, Kewei [1 ]
Zong, Qingyu [2 ]
Tu, Yalan [2 ]
Dong, Yansong [2 ,3 ,4 ]
Yuan, Youyong [1 ,2 ,5 ]
机构
[1] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Biomed Sci & Engn, Guangzhou Int Campus, Guangzhou 511442, Peoples R China
[2] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China
[3] South China Univ Technol, Key Lab Biomed Engn Guangdong Prov, Guangzhou 510006, Peoples R China
[4] South China Univ Technol, Innovat Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China
[5] Guangzhou Regenerat Med & Hlth Guangdong Lab, Bioland Lab, Guangzhou 510005, Peoples R China
基金
中国国家自然科学基金;
关键词
Glutathione response; Multidrug resistance; poly(disulfide);
D O I
10.1016/j.biomaterials.2020.120649
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
High intracellular glutathione (GSH) levels play an important role in multidrug resistance (MDR) in cancer cells. It remains challenging to develop a drug delivery system that is simultaneously capable of GSH depletion and drug activation for multidrug resistance reversal. Herein, we designed a polyprodrug (denoted as PSSD) based on poly(disulfide) conjugated with doxorubicin (DOX) on the polymer side chains that exhibits GSH depletion and cascade DOX activation for drug resistance reversal. The poly(disulfide) backbone with a high disulfide density depletes intracellular antioxidant GSH via the disulfide-thiol exchange reaction to disrupt intracellular redox homeostasis in cells. Simultaneously, DOX can be activated through a cascade reaction, and degradation of the poly(disulfide) backbone further facilitates its drug release. Therefore, poly(disulfide) can be used as a GSH scavenger to reverse MDR as well as a prodrug backbone to target high intracellular GSH levels in cancer cells, providing a general strategy for drug resistance reversal.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro
    Guang-Dong Pan
    World Journal of Gastroenterology, 2009, 15 (04) : 431 - 440
  • [22] Reversal of multi-drug resistance in vitro by fatty acid PEG fatty acid diesters
    Buckingham, LE
    Balasubramanian, M
    Safa, AR
    Shah, H
    Komarov, P
    Emanuele, RM
    Coon, JS
    INTERNATIONAL JOURNAL OF CANCER, 1996, 65 (01) : 74 - 79
  • [23] New taxanes as highly efficient reversal agents for multi-drug resistance in cancer cells
    Ojima, I
    Bounaud, PY
    Takeuchi, C
    Pera, P
    Veith, JM
    Bernacki, RJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 208 - MEDI
  • [24] Clinical studies of reversal of drug resistance based on glutathione
    Calvert, P
    Yao, KS
    Hamilton, TC
    O'Dwyer, PJ
    CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 112 : 213 - 224
  • [25] Outsmarting multi-drug resistance in uncertain times
    不详
    JAC-ANTIMICROBIAL RESISTANCE, 2020, 2 (04):
  • [26] Strategies to Combat Multi-Drug Resistance in Tuberculosis
    Singh, Vinayak
    Chibale, Kelly
    ACCOUNTS OF CHEMICAL RESEARCH, 2021, 54 (10) : 2361 - 2376
  • [27] Multi-drug resistance in chronic lymphocytic leukemia
    Friedenberg, WR
    Spencer, SK
    Musser, C
    Hogan, TF
    Rodvold, KA
    Rushing, DA
    Mazza, JJ
    Tewksbury, DA
    Marx, JJ
    LEUKEMIA & LYMPHOMA, 1999, 34 (1-2) : 171 - 178
  • [28] Is Glycyrrhizin the Magic Bullet for Multi-drug Resistance?
    Hazlett, Linda D.
    Ekanayaka, Sandamali Amarasingha
    McClellan, Sharon A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [29] Distribution and drug resistance analysis of multi-drug resistant bacteria in hospital
    Kong, Qingling
    Kang, Congli
    Liu, Hongqiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (03): : 2648 - 2653
  • [30] Regulation of multi-drug resistance in Erwinia chrysanthemi
    Ravirala, R.
    Francisco, M. San
    Lee, C.
    PHYTOPATHOLOGY, 2005, 95 (06) : S86 - S86